Acute Myeloid Leukemia Phase III Clinical Trials Activates 25 Sites and Gains Momentum with Prominent Leukemia-Focused Investigator at Helm

Acute Myeloid Leukemia Phase III Clinical Trials Activates 25 Sites and Gains Momentum with Prominent Leukemia-Focused Investigator at Helm

Rafael Pharmaceuticals reported that 25 sites have been activated in the pivotal Phase III ARMADA 2000 clinical trial of CPI613® (devimistat) in older patients with relapsed or refractory acute myeloid leukemia (AML). Dr. Jorge Cortes, Director of Georgia Cancer...

Pin It on Pinterest